Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade

This article was originally published in The Pink Sheet Daily

Executive Summary

Policy changes since FDA's first biosimilar approval produce a label that is more clearly different than, but also more closely tied to, its brand reference.

You may also be interested in...



US FDA Again Looks Outside Generic Drugs Office For New Director

Sally Choe, who has been working in the Office of Translational Sciences, will take over for Kathleen Uhl in March.

US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?

Agency has scheduled only two advisory committee meetings in 2017; does it indicate the agency plans to conduct fewer meetings going forward?

Inflectra Launch Prep Continues Post-Deadline, Pfizer Says

The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS079376

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel